Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important ste...

Armis, the cyber exposure management & security company, today announced the launch of the Armis Developer Portal. The centralized knowledge hub enables organizations to seamlessly integrate Armis’ comprehensive asset intelligence into their existing technology stacks. Developers, customers and partners can fuel their applications using the Armis API, transforming static asset inventories into real-time, actionable insights that drive innovation and automation. “True security is only poss...